Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatin-based combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for more effective treatments for cisplatin-resistant disease. In this study, it is shown that two of four cell lines derived from human non-seminomatous testicular germ cell tumours are exceptionally sensitive to temozolomide, a new imidazotetrazine which can cross the blood-brain barrier in mice. In addition, three pairs of cisplatin-resistant sublines show little cross-resistance to temozolomide. These data suggest that temozolomide might have activity against non-seminomatous testicular germ cell tumours which have relapsed following cisplatin-containing chemotherapy, and could have a role in the treatment of patients with metastatic lesions in the brain.
Pera
M F
MF
Department of Zoology, Oxford University, UK.
Köberle
B
B
Masters
J R
JR
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D002945:Cisplatin / Q000494:pharmacology; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D004351:Drug Resistance; D004354:Drug Screening Assays, Antitumor; D018237:Germinoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D000077204:Temozolomide; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014407:Tumor Cells, Cultured / Q000187:drug effects; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D003606:Dacarbazine; D002945:Cisplatin; D000077204:Temozolomide